CTEV
Claritev Corporation
CTEV has the edge over NVO overall, supported by stronger modeled upside and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
CTEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
CTEV's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CTEV PE Valuation
CTEV has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CTEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| Stable | |
| Limited | |
| High |
CTEV has the edge over NVO on the outlook, with more favorable profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CTEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$16.42 | +$4.87 |
| Q2 2026 | -$17.01 | +$24.30 |
| Q1 2026 | -$17.33 | +$55.77 |
| Q4 2025 | -$17.30 | +$84.62 |
| Q3 2025 | -$21.29 | +$73.36 |
| Q2 2025 | -$41.31 | +$30.69 |
| Q1 2025 | -$73.10 | -$34.30 |
| Q4 2024 | -$101.92 | -$96.32 |
CTEV is still losing money, but far less than before: $16.42 per share over the past year, against $101.92 at its worst in late 2024.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CTEV on earnings quality, reporting a profit while its opponent remains loss making.
CTEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $268.3M | +9.1% |
| Q2 2026 | $257.5M | +6.6% |
| Q1 2026 | $244.7M | +5.8% |
| Q4 2025 | $246.6M | +6.2% |
| Q3 2025 | $246M | +6.7% |
| Q2 2025 | $241.6M | +3.5% |
| Q1 2025 | $231.3M | -1.4% |
| Q4 2024 | $232.1M | -4.9% |
CTEV's revenue has grown year over year for six quarters in a row: $268M last quarter, up 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +3.6 points |
| Q2 2026 | 9.1% | +2.2 points |
| Q1 2026 | 2.7% | -1.5 points |
| Q4 2025 | -3.1% | +15 points |
| Q3 2025 | 4.1% | +151 points |
| Q2 2025 | 6.9% | +231 points |
| Q1 2025 | 4.2% | +212 points |
| Q4 2024 | -18% | -35 points |
CTEV's operating margin was 7.7% last quarter, up 3.6 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CTEV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CTEV on profitability, with a higher operating margin.
CTEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.2M | -$9.9M |
| Q2 2026 | $54.6M | +49% |
| Q1 2026 | -$92.5M | -$23.6M |
| Q4 2025 | $36.4M | +$100.2M |
| Q3 2025 | -$16.3M | -140% |
| Q2 2025 | $36.6M | +$43.6M |
| Q1 2025 | -$68.9M | -459% |
| Q4 2024 | -$63.8M | -$60.2M |
CTEV's free cash flow was −$28M over the past year, against −$113M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CTEV on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +10.3K shares |
| 1 year | +3% | +495K shares |
| 3 years | +5% | +814K shares |
| 5 years | +4% | +653K shares |
| Available history | +562% | +14.4M shares |
CTEV has 17M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CTEV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CTEV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.4x | High |
| Q2 2026 | 9.6x | High |
| Q1 2026 | 9.7x | High |
| Q4 2025 | 9.6x | High |
| Q3 2025 | 10.3x | High |
| Q2 2025 | 52.3x | High |
| Q1 2024 | 85.5x | High |
| Q4 2023 | 7.7x | High |
CTEV's net debt is about 9.4 years of its operating earnings (EBITDA), down from 10 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over CTEV on leverage, with a lower net debt burden relative to earnings.
CTEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.9 | Neutral |
| Stochastic | 21.6 | Neutral |
CTEV's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CTEV PE vs Healthcare Sector
| Metric | CTEV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTEV has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CTEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.9 | 13% above |
| 20 week MA | $29.1 | 7.6% below |
| 50 week MA | $26.9 | 0.1% below |
| 100 week MA | $32.3 | 17% below |
| 200 week MA | $36.3 | 26% below |
CTEV has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 26% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CTEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.8 | $357.2 | -8.1% |
| 2021 | $357.2 | $176.8 | -51% |
| 2022 | $176.8 | $47.6 | -73% |
| 2023 | $47.6 | $57.6 | +21% |
| 2024 | $57.6 | $17.5 | -70% |
| 2025 | $17.5 | $42.0 | +140% |
| 2026 YTD | $42.0 | $26.9 | -36% |
CTEV's yearly returns have swung widely, from +140% in 2025 to −73% in 2022. It's down 36% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CTEV on returns for 2026, with the stronger performance.